Self-Paced Course: Molecular Biology Techniques 2024

Self-Paced Course: Molecular Biology Techniques 2024
Go back

Overview

The application and development of molecular biology techniques are essential for new discoveries in the life sciences. The self-paced course “Molecular Biology Techniques: Comprehensive Approaches for Educators and Enthusiasts“, organised by EMBL’s Science Education and Public Engagement team in partnership with Merck, provides an insight into the key molecular biology techniques used in modern research and explores their effective teaching methods in the classroom.

This free online course will run from 21 October to 1 December 2024. Participants can join at any time and progress through the course material at their convenience. No live or Q&A sessions are intended. Upon completion, participants can earn a certificate of attendance by completing a short feedback questionnaire.

Dates                         Duration                    Weekly study                Format

21 Oct – 1 Dec              6 weeks                        2 hours                        100% online    

Please note: This course reuses content from the 2021 EMBL virtual LearningLAB “Taking a Fresh Look: Teaching Molecular Biology Techniques in the Classroom“.  In addition to the previous content, pre-recorded Zoom scientific discussions and new learning and teaching resources have been added.

Who is this course for?
This course is designed for formal and informal educators, including teacher trainers and educators in training. It is also suitable for science professionals and anyone interested in learning more about molecular biology techniques.

register now

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

read more
Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

read more
Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp